10/28/20 6:09 AMNYSE : RDYDr. Reddy's Laboratories Announces Appointment of New Chief Financial OfficerDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Officer (Designate) on November 2, 2020. The Board of Directors at their meeting held today, has approved his appointment as a Chief Financial Officer (KMP*) of the Company effective December 1, 2020. In a career spanning over 33 years, Parag has held several leadership positions, contributing significantly to tRHEA-AIvery positive
10/28/20 5:40 AMNYSE : RDYDr. Reddy's Q2 & H1 FY21 Financial ResultsDr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year ended September 30, 2020. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS). Q2 Performance Summary H1 Performance Summary Rs. 4,897 Cr Rs. 9,314 Cr Revenue Revenue [Up: 11% QoQ; 2% YoY] [Up: 8% YoY] 53RHEA-AIneutral
10/20/20 3:44 AMNYSE : RDYDr. Reddy's announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC(R) in the U.S. MarketDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC(R), in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy's OTC Famotidine Tablets USP, 10 mg andRHEA-AIneutral
10/17/20 6:44 AMNYSE : RDYDr. Reddy's and RDIF receive approval to conduct clinical trial for Sputnik V vaccine in IndiaDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. This will be a multi-center and randomized controlled study, which will include safety and immunogenicity study. Earlier in September 2020,RHEA-AIvery positive
10/12/20 8:51 AMNYSE : RDYDr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting. Summary of Events Event Date and Time Medium Release of financial results October 28th, after the Board Meeting Stock Exchange, Media, Company website, Business wire, Email Press meet presentation Will be available on the Company's website Company's website www.drredRHEA-AIneutral
10/05/20 5:27 AMNYSE : RDYDr. Reddy's Laboratories Joins Science Based Targets initiative (SBTi) and Sets 2030 GHG Emission TargetsDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative's (SBTi) business ambition for 1.5?C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact. The Company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 percent by 2030 from a FY2017-18 base year, which are in line withRHEA-AIvery positive
10/03/20 2:57 AMNYSE : RDYDr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. MarketDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use. "We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients," says MRHEA-AIneutral
10/01/20 4:08 AMNYSE : RDYDr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. MarketDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets, approved by the U.S. Food and Drug Administration (USFDA). The Sensipar brand and generic market had U.S. sales of approximately $312 million MAT for the most recent twelve months endinRHEA-AIneutral
09/26/20 6:03 AMNYSE : RDYDr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. MarketDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.Reddy's") today announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera(R) (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA). The Tecfidera(R) brand and generic market had U.S. sales of approximately $3.8RHEA-AIneutral
